Benralizumab for treating eosinophilic oesophagitis in people aged 12-65 years

Benralizumab is currently in clinical development for treating eosinophilic oesophagitis (EoE). EoE
is a condition in which the oesophagus (gullet) becomes inflamed as a result of an allergic reaction.
The inflammation is caused by a type of white blood cell called eosinophils. The oesophagus
transmits food from the mouth to the stomach, so the inflammation makes swallowing difficult as
the oesophagus becomes narrower than usual.